| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| ofatumumab | b-lymphocyte antigen cd20 | biotech | NA | drugbank , DGIDB | Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neoplasm Metastasis[MeSHID:D009362] Chronic Lymphocytic Leukemia[MeSHID:D015451] Syndrome[MeSHID:D013577] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma Non-Hodgkin[MeSHID:D008228] Diffuse Large B-Cell Lymphoma[MeSHID:D016403] Rheumatoid Arthritis[MeSHID:D001172] |
31.83 | approved | antibody,inhibitor |
| ofatumumab | leukocyte surface antigen leu-16 | NA | Successful target | TTD , DGIDB | Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neoplasm Metastasis[MeSHID:D009362] Chronic Lymphocytic Leukemia[MeSHID:D015451] Syndrome[MeSHID:D013577] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma Non-Hodgkin[MeSHID:D008228] Diffuse Large B-Cell Lymphoma[MeSHID:D016403] Rheumatoid Arthritis[MeSHID:D001172] |
31.83 | approved | unknown |
| ofatumumab | leukocyte surface antigen leu-16 | NA | Successful target | TTD , DGIDB | Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neoplasm Metastasis[MeSHID:D009362] Chronic Lymphocytic Leukemia[MeSHID:D015451] Syndrome[MeSHID:D013577] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma Non-Hodgkin[MeSHID:D008228] Diffuse Large B-Cell Lymphoma[MeSHID:D016403] Rheumatoid Arthritis[MeSHID:D001172] |
31.83 | approved | antibody |
| ofatumumab | leukocyte surface antigen leu-16 | NA | Successful target | TTD , DGIDB | Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neoplasm Metastasis[MeSHID:D009362] Chronic Lymphocytic Leukemia[MeSHID:D015451] Syndrome[MeSHID:D013577] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma Non-Hodgkin[MeSHID:D008228] Diffuse Large B-Cell Lymphoma[MeSHID:D016403] Rheumatoid Arthritis[MeSHID:D001172] |
31.83 | approved | inhibitor |
| ofatumumab | b-lymphocyte antigen cd20 | biotech | NA | drugbank , DGIDB | Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neoplasm Metastasis[MeSHID:D009362] Chronic Lymphocytic Leukemia[MeSHID:D015451] Syndrome[MeSHID:D013577] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma Non-Hodgkin[MeSHID:D008228] Diffuse Large B-Cell Lymphoma[MeSHID:D016403] Rheumatoid Arthritis[MeSHID:D001172] |
31.83 | approved | antibody |
| click here to return to the previous page | ||||||||